How much is the FDA not telling us? On Page 252 of Medication Madness, Dr. Breggin says:                       “From my FOIA (Freedom of Information Act) inquiries to the FDA, I had found that initial drafts of the Prozac label had listed “depression” and “abnormal thoughts” as two of the three most commonly reported adverse reactions to the drug. In these drafts, the company in effect admitted that its own principal investigators--the scientists conducting the clinical trials--were reporting that their patients frequently became more depressed on Prozac. Combined with an increase in “abnormal thoughts,”  this indicated that the drug was making many people worse and even potentially dangerous. I then discovered that shortly before the label was made official, “abnormal thoughts” was dropped from the list of top three adverse effects and replaced with the more innocuous “abnormal dreams.” Then, on the last day before the label was officially approved, an FDA official scratched out “depression” from its prominent place in the label. Depression as a serious adverse effect of Prozac went from being “frequent” to being nonexistent.” The company (Eli Lilly) in combination with the FDA, had expurgated some of the most damning information from the label shortly before it’s publication...” Return to Homepage Have you read about the Scott Reuben Pain Management Fraud Case?